Prashant Kapoor
Mayo Clinic in Rochester · Mayo Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Prashant Kapoor as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:20 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07420959 · ABBV-383 for the Treatment of Relapsed Refractory Waldenström MacroglobulinemiaMayo Clinic · recruiting · Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia · principal investigator
- Ph1/Ph2NCT05392946 · Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL StudyMayo Clinic · active not recruiting · Plasma Cell Myeloma · principal investigator
- Ph1/Ph2NCT04764942 · Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE TrialMayo Clinic · active not recruiting · Recurrent Multiple Myeloma, Refractory Multiple Myeloma · principal investigator
- Ph2NCT03202628 · Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple MyelomaMayo Clinic · completed · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2011 to 2026Named on NCT03202628
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:20 UTC. The ranking covers the 200 most relevant of 56 PubMed records, and a shared surname and initials can bring in a namesake. All 56 on PubMed
- 271 citationsRCR 11.9
- 232 citationsRCR 10.3
- Early goal-directed therapy in moderate to high-risk cardiac surgery patients.Ann Card Anaesth · 2008108 citationsRCR 4.0
- Quantification of clonal circulating plasma cells in relapsed multiple myeloma.Br J Haematol · 201473 citationsRCR 2.1
- Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib.Blood Cancer J · 201564 citationsRCR 1.9
- Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells.Am J Hematol · 202058 citationsRCR 2.4
- False positive rate of thoracic outlet syndrome diagnostic maneuvers.Electromyogr Clin Neurophysiol · 200857 citationsRCR 2.8
- 57 citationsRCR 1.9
- Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.Blood Adv · 202253 citationsRCR 3.7
- 52 citationsRCR 1.7